Taiwan Liposome Company, Ltd. (TLC:NASDAQ) Investor Relations Material

Overview

Taiwan Liposome Company (TLC) is a clinical-stage pharmaceutical company that specializes in developing and commercializing nanomedicines that use lipid-assembled drug delivery platforms combined with approved active pharmaceutical ingredients. The nanomedicines created by TLC enable faster onset and longer duration of treatment with improved concentration at target tissues and reduced exposure to unwanted systemic effects. Their extensive experience in liposome science has enabled them to create best-in-class nanomedicines that improve the efficacy and safety of treatments for a range of diseases.

Frequently Asked Questions

What is Taiwan Liposome Company, Ltd.'s ticker?

Taiwan Liposome Company, Ltd.'s ticker is TLC

What exchange is Taiwan Liposome Company, Ltd. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Taiwan Liposome Company, Ltd.'s headquarters?

They are based in Taipei, Taiwan

How many employees does Taiwan Liposome Company, Ltd. have?

There are 51-200 employees working at Taiwan Liposome Company, Ltd.

What is Taiwan Liposome Company, Ltd.'s website?

It is https://www.tlcbio.com/en-global

What type of sector is Taiwan Liposome Company, Ltd.?

Taiwan Liposome Company, Ltd. is in the Healthcare sector

What type of industry is Taiwan Liposome Company, Ltd.?

Taiwan Liposome Company, Ltd. is in the Biotechnology industry

Who are Taiwan Liposome Company, Ltd.'s peers and competitors?

The following five companies are Taiwan Liposome Company, Ltd.'s industry peers:

- Gamida Cell Ltd.

- Clearside Biomedical

- Marinus Pharmaceuticals

- Hepion Pharmaceuticals, Inc.

- Amplia Therapeutics